Podcasts about standard of care

Join us for an engaging discussion with Chad Clary where we explore how architectural projects differ from movies and video games in terms of crediting contributors. We talk about whether the industry needs a better system for recognizing all those involved in building projects. The conversation also covers the critical importance of specificity in architectural documentation, examining how evolving professional roles affect design intent preservation while meeting contractor expectations.Episode Links:The Barnes Foundation by TWBTA-----Have a question for the hosts? Ask it at AskArchispeak.comThank you for listening to Archispeak. For more episodes please visit https://archispeakpodcast.com.Support Archispeak by making a donation.

Learn how your treatment plan is decided and terms you may seeWe continue our series to help you understand cancer and its treatment. This week we focus on surgery, the oldest form of cancer treatment. Learn about surgery timing, types of cancer surgery, and how NCCN evidence-based guidelines provide a standard treatment path no matter where you are.In this Episode:02:58 - Wisconsin-Cheese, UFOs, and Booyah Stew04:52 - Anna Quindlen: Get a Life Where You Are Generous"08:06 - Medical Specialists Involved in Cancer Care08:52 - Treatment Decisions, Tumor Board and NCCN Guidelines12:03 - Adjuvant and Neoadjuvant Therapy13:13 - Surgery Timing, Reasons and Types18:00 - Discussion - NCCN and Role of Research24:34 - Reeves Keyworth:“On Loved Ones Telling the Dying to ‘Let Go”23:54 - OutroSurgery, radiation therapy, and chemotherapy alone or in combination are the most-common methods used to treat cancer. Specific treatment varies depending on the kind of cancer, the extent of the disease, its rate of progression, and the condition of the person. Surgery alone may not result in a cure and often chemotherapy and/or radiation are needed after surgery. Learn all about surgery and the guidelines your doctor will be following for your treatment.Support the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org

CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/DefiningtheStandardofCareandOptimalSequencinginBRAFMutantmCRcSecondLineandBeyond/32944/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, the management of treatment-related adverse events.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MFK865. CME/AAPA credit will be available until March 10, 2026.Leveling the Standard of Care in Hemophilia A: Insights & Strategies for Developing Effective, Personalized Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MFK865. CME/AAPA credit will be available until March 10, 2026.Leveling the Standard of Care in Hemophilia A: Insights & Strategies for Developing Effective, Personalized Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MFK865. CME/AAPA credit will be available until March 10, 2026.Leveling the Standard of Care in Hemophilia A: Insights & Strategies for Developing Effective, Personalized Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MFK865. CME/AAPA credit will be available until March 10, 2026.Leveling the Standard of Care in Hemophilia A: Insights & Strategies for Developing Effective, Personalized Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MFK865. CME/AAPA credit will be available until March 10, 2026.Leveling the Standard of Care in Hemophilia A: Insights & Strategies for Developing Effective, Personalized Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MFK865. CME/AAPA credit will be available until March 10, 2026.Leveling the Standard of Care in Hemophilia A: Insights & Strategies for Developing Effective, Personalized Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MFK865. CME/AAPA credit will be available until March 10, 2026.Leveling the Standard of Care in Hemophilia A: Insights & Strategies for Developing Effective, Personalized Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MFK865. CME/AAPA credit will be available until March 10, 2026.Leveling the Standard of Care in Hemophilia A: Insights & Strategies for Developing Effective, Personalized Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

Judy and Dennis (TheVascular Guy) discuss the importance of patient-centered care, the challenges of managing patients with sensitive skin sensitivities, and the need for alternative solutions like Covalon's dressings. They also explore the potential trend of increased skin sensitivity, the use of chlorhexidine and silicone-based dressings for patient care, and the importance of thorough patient assessment and providing multiple treatment options. The duo conclud by discussing the challenges of implementing cultural and administrative changes in healthcare systems, the importance of patch testing with products, and the need for improved practices in managing catheters.Thank you to Covalon for sponsoring this Podcast! www.covalon.comSupport the show

Welcome to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Kevin Kalinsky, a leading breast medical oncologist and director of the breast cancer program at the Winship Cancer Institute of Emory University. Join us as we dive deep into the complexities of hormone receptor-positive breast cancer treatment. We discuss the latest advancements in treatment algorithms, including the use of OncotypeDX in premenopausal versus postmenopausal women, the role of ovarian function suppression, and the implications of new approvals like Inavolisib and CDK4-6 inhibitors. Key topics covered in this episode: •⁠  ⁠The significance of recurrence scores in dictating adjuvant chemotherapy •⁠  ⁠The ongoing OFSET trial and its potential impact on treatment decisions •⁠  ⁠Insights into the use of genomic assays like MammaPrint and RS-Clin •⁠  ⁠The evolving landscape of treatment options for locally advanced and metastatic breast cancer •⁠  ⁠The latest on PARP inhibitors, T-DXd, and other novel therapies Whether you're a medical professional or someone interested in the latest in oncology, this episode is packed with valuable insights and clinical pearls. Don't forget to subscribe for more discussions on cancer treatment, FDA approvals, and conference highlights! YouTube: https://youtu.be/_icBN3J3Bc0 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers #OncologyBrothers #HR+ #breastcancer   #HormoneReceptorPositiveCancer #oncbrothers  #Podcast

This podcast was edited on a plane ride to Japan, and the intro was recorded in a bathroom while my kids slept off the jet lag. It's still good. I recently went down with Ben Greenzweig, the Executive Director of the non-profit Living Water Brain Treatment Center in Myrtle Beach, South Carolina. We are—right now—providing TMS treatment and, soon to be more, in a local community in Ben's beloved home of Horry County. There are 400,000 residents and less than 30 psychiatric inpatient beds in the county. There are not enough services to meet the needs he saw in his community—so he started Living Water to help. I'll remind readers that not only did he write an article about it, but he is also running a non-profit. Thus, consider donating.The audio from today's podcast was recorded mainly on my phone, which I had in my pocket as I gave the talk. Please share it with friends. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit thefrontierpsychiatrists.substack.com/subscribe

Dr Evelyn Ainsley McWilliams joins Ethics Talk to discuss her article, coauthored with Dr Lisa Bayer: “How Should Intensity and Duration of Pain Inform Standard of Care for Pain Management in Non-Labor and Delivery OB/GYN Procedures?”  Recorded December 3, 2024.  Read the full article for free at JournalOfEthics.org

Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, and Dr. Angela Cassano, PharmFusion Founder and owner, discuss Dr. Cassano's personal pharmacogenomics testing and how the results impacted her breast cancer treatment, the tamoxifen and CYP2D6 pharmacogenomics clinical utility research currently available, whether CYP2D6 testing for patients prior to tamoxifen is National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) recommended, and whether insurers in the United States reimburse the testing. This is a must listen for those interested in the clinical pharmacogenomics' current landscape and a pharmacist-patient's perspective about PGx testing.   

Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, and Dr. Angela Cassano, PharmFusion Founder and owner, discuss Dr. Cassano's personal pharmacogenomics testing and how the results impacted her breast cancer treatment, the tamoxifen and CYP2D6 pharmacogenomics clinical utility research currently available, whether CYP2D6 testing for patients prior to tamoxifen is National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) recommended, and whether insurers in the United States reimburse the testing. This is a must listen for those interested in the clinical pharmacogenomics' current landscape and a pharmacist-patient's perspective about PGx testing.   

Join us for the season premiere of EASL Studio Season 8 as we unpack key insights from the Steatotic Liver Disease (SLD) Summit. Explore the evolving consensus on patient trajectories, advancements in ALD and MetALD treatment pathways, and the latest endpoint discussions. The episode also highlights a holistic approach to diagnosing and managing comorbidities and revisits the standard of care in light of breakthroughs in MASH treatments.Moderator: Aleksander KragFaculty: Cyrielle Caussy, Sven Francque and Brian LeeThis EASL Studio is supported by Madrigal. EASL has received no input from Madrigal with regards to the content of this programme.Related episodesS7E3 – The changing face of Steatotic Liver Disease: Navigating new opportunities and emerging challengesEASL Studio at the Congress 2024: SLD nomenclature: Need for refinement?EASL Studio at the Congress 2024: MASLD anno 2024: A rapidly changing landscapeEASL Studio from EASL Congress 2023 – Steatotic liver disease global consensus to change nomenclatureAll EASL Studio Podcasts are available on EASL Campus.

This episode is a continuation of last week. It focuses on both the positive and negative medical experiences of people who have gone through infertility and loss. People wrote in and sent clips sharing about either a medical provider that was extremely helpful and supportive or one that was not supportive and needs improvement. Listen as they share their experiences and show there is no true standard of care when it comes to infertility or pregnancy and infant loss.

This episode focuses on both the positive and negative medical experiences of people who have gone through infertility and loss. People wrote in and sent clips sharing about either a medical provider that was extremely helpful and supportive or one that was not supportive and needs improvement. Listen as they share their experiences and show there is no true standard of care when it comes to infertility or pregnancy and infant loss.

Send us a textThe Modern Urologist Podcast has launched a new miniseries, Precision Oncology and Prostate Cancer: The New Standard of Care, hosted by Dr. Paul Sieber and Ashleigh Renitsky, Oncology PA. This series will focus on the evolving role of genetic testing in prostate cancer care and its impact on personalized patient treatment plans.Episode #1 - Genetic testing basicsThe first installment will provide an overview of genetic testing, highlighting the difference between germline and somatic testing, and their implications for personalized treatment. This episode emphasizes the importance of integrating streamlined testing protocols into clinical practice, understanding test results to tailor therapies for patients, and leveraging genetic counselors. 

What is the standard of care? It's not a single document like the Declaration of Independence, so what is it and who decides what it is? In this episode Andrew talks through a few resources to help you find, establish, and implement the dental standard of care in your offices. He also gives a strong warning the the RDH profession... Resources: Https://www.perio.org Https://aap.org https://aacariology.org/about/

What is the standard of care? It's not a single document like the Declaration of Independence, so what is it and who decides what it is? In this episode Andrew talks through a few resources to help you find, establish, and implement the dental standard of care in your offices. He also gives a strong warning the the RDH profession... Resources: Https://www.perio.org Https://aap.org https://aacariology.org/about/

On this episode of IPA's What, Why & How podcast, Kate Gainer welcomes pharmacy colleagues from Idaho and Alaska to share what standard of care means in their respective states and how this regulatory framework allows pharmacists to better care for their patients. To Learn More: Standard of Care Resources | Standard of Care Symposium (February 22, 2025) Jennifer Adams, PharmD, EdD, a graduate of Boise State University, Idaho State University and The George Washington University, is currently employed as Associate Dean for Academic Affairs at Idaho State University. Her previous experience includes working in hospital and community pharmacy settings, as well as at the American Pharmacists Association (APhA), helping student pharmacists develop as professionals and leaders in the profession. Dr. Adams also served for nearly 10 years as the Senior Student Affairs Advisor at the American Association of Colleges of Pharmacy (AACP), providing leadership and oversight for national student affairs activities and recruitment. Nicki Chopski earned her PharmD from Idaho State University College of Pharmacy in 1997. In 2007, as a hospital pharmacist, Nicki was appointed to the Idaho Board of Pharmacy, serving for 12 years before becoming its Executive Director in 2019. In her current role as Bureau Chief of Health Professions for the Idaho Division of Occupational and Professional Licenses, she serves as the Executive Officer for the Boards of Medicine, Nursing and Pharmacy. Brandy Seignemartin, PharmD, Executive Director of the Alaska Pharmacy Association and Clinical Assistant Professor at the UAA ISU Doctor of Pharmacy Program, has a longstanding commitment to advancing the pharmacy profession. A graduate of The Washington State University College of Pharmacy and Pharmaceutical Sciences, Dr. Seignemartin's passion for advocacy took root during her time as a student pharmacist, where she successfully led the passage of legislation in the Washington State legislature allowing interprofessional precepting between nursing, pharmacy, and medicine. In her academic role, Dr. Seignemartin is dedicated to mentoring the next generation of pharmacists, receiving the Most Influential Faculty Award in 2024. Ashley Schaber, PharmD, MBA, BCPS, is currently the Chair of the Alaska Board of Pharmacy. She graduated pharmacy school from the University of Georgia in 2006, completed a pharmacy practice residency, and has worked in health system pharmacy since 2007. She is board certified in Pharmacotherapy and holds her Master's of Business Administration with a focus on healthcare.

Dr. Linda Duska and Dr. Domenica Lorusso discuss the practice-changing results of the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, which evaluated pembrolizumab plus chemoradiotherapy as treatment for previously untreated, high-risk, locally advanced cervical cancer. TRANSCRIPT  Dr. Linda Duska: Hello, I'm Linda Duska, your guest host of the ASCO Daily News Podcast today. I'm a professor of obstetrics and gynecology and serve as the associate dean for clinical research at the University of Virginia School of Medicine. On today's episode, we'll be discussing a new standard of care for previously untreated, high- risk locally advanced cervical cancer. This follows the ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, which I will be referring to as KEYNOTE-A18 for the rest of this podcast, which demonstrated that pembrolizumab plus chemoradiotherapy improved both progression-free and overall survival compared to chemoradiotherapy alone. I was a co-author of this study, and I'm delighted to be joined today by the study's lead investigator, Dr. Domenica Lorusso, for today's discussion. She is also a professor of obstetrics and gynecology. She's at Humanitas University Rosano and the director of the Gynecologic Oncology Unit at the Humanitas Hospital San Pio in Milan, Italy. Our full disclosures are available in the transcript of this episode. Dr. Lorusso, it's great to be speaking with you today. Dr. Domenica Lorusso: Thank you, Linda. It's a great pleasure to be here. Thank you. Dr. Linda Duska: So I was hoping you could start us out with some context on the challenges associated with treating patients with high-risk, locally advanced cervical cancer. Dr. Domenica Lorusso: Yes. I have to make a disclosure because in my experience as a gynecologist, cervical cancer patients are the most difficult patients to treat. This is a tumor that involves young patients [who often have] small kids. This is a very symptomatic tumor. More than 50% of patients report pain. Sometimes the pain is difficult to control because there is an infiltration of the pelvic nerves and also a kind of vaginal discharge, so it's very difficult to treat the tumor. Since more than 25 years, we have the publication of 5 randomized trials that demonstrate that when we combine platinum chemotherapy to radiation treatment, we increase overall survival by 6%. This is the new standard of care – concurrent chemoradiation plus brachytherapy. This is a good standard of care because particularly modern, image-guided radiotherapy has reported to increase local control. And local control in cervical cancer translates to better overall survival. So modern radiotherapy actually is able to cure about 75% of patients. This is what we expect with chemoradiation right now. Dr. Linda Duska: So what are the key takeaways of A18? This is a really exciting trial, and you've presented it a couple of times. Tell us what are the key takeaways that you want our listeners to know. Dr. Domenica Lorusso: Linda, this is our trial. This is a trial that we did together. And you gave me the inspiration because you were running a randomized phase 2 trial exploring if the combination of pembrolizumab to concurrent chemoradiation was able to give signals of efficacy, but also was feasible in terms of toxicity. There were several clinical data suggesting that when we combine immunotherapy to radiotherapy, we can potentially increase the benefit of radiotherapy because there is a kind of synergistic effect between the two strategies. Radiotherapy works as a primer and immunotherapy works better. And you demonstrated that it was feasible to combine immunotherapy to concurrent chemoradiation. And KEYNOTE-A18 was based on this preliminary data. We randomized about 1,060 patients to receive concurrent chemoradiation and brachytherapy or concurrent chemoradiation and brachytherapy in combination with pembrolizumab followed by pembrolizumab for about two years. Why two years? Because in more than 80% of cases, recurrence in this patient population occurred during the first two years. So the duration of treatment was based on the idea to provide protection to the patient during the maximum time of risk. And the trial had the two primary endpoints, progression free and overall survival, and met both the endpoints, a significant 30% reduction in the risk of progression that was confirmed. At the 3-year follow up, the observation was even better, 0.68. So 32% reduction in the risk of progression. And more importantly, because this is a curative setting, 33% reduction in the risk of death was reported in the experimental arm when pembro was combined with chemoradiation. Dr. Linda Duska: That's amazing. I wanted to ask you, a prior similar study called CALLA was negative. Why do you think A18 was positive? Dr. Domenica Lorusso: Linda, there are several discussions about that. I had the possibility to discuss several times with the PI of CALLA, Brad Monk. The idea of Brad is that CALLA was negative because of using durvalumab instead of PD-1 inhibitor, which is pembrolizumab. I do not have exactly the same impression. My idea is that it's the kind of patient population enrolled. The patient population enrolled in KEYNOTE-A18 was really a high-risk population; 85% of that patient were node positive, where the definition of node positivity was at least 2 lymph nodes in the pelvis with a short diameter of 1.5. So, we are very confident this patient was node-positive, 55% at the grade 3 and 4 diseases. So this is really a high-risk population. I remember at the first presentation of CALLA, I was honored to discuss the CALLA trial when it was first presented at IGCS a few years ago. And when I received the forest plot of Calla, it was evident to me that in patients with stage III and node positive there was a signal of efficacy. And we have a huge number of patients with node positive. So in my opinion this is the reason why KEYNOTE-A18 is positive. Dr. Linda Duska: Yeah, I agree with you. I've thought about it a lot and I think you're right about that. The INTERLACE trial results were recently published. How should we interpret these results in the context of A18? Dr. Domenica Lorusso: So it's very difficult to compare the 2 trials. First of all, in terms of population. The population enrolled in INTERLACE is a low-risk, locally advanced but low risk population; 76% were stage II, 10% were stage I, 60% were node-negative patients. So, first of all, the population is completely different. Second is the type of radiotherapy that was provided. INTERLACE is a 10-year long trial, but in 10 years the quality and the technique of radiotherapy completely changed. Only 30% of patients in INTERLACE received what we call the modern image-guided brachytherapy, which is important because it provides local control and local control increases overall survival. And third, we read the paper. I'm not a methodologist, but there are some methodological biases in the paper. All the statistical design of the trial was based on PFS, but PFS was evaluated at physician description. And honestly, I never saw a trial that had no pre-specified timeline for radiological evaluation. It's very difficult to evaluate progression in cervical cancer because the fibrosis related to radiotherapy changes the anatomy in the pelvis. And I think that the radiological evaluation is important to address if the patient is progressing or not. Particularly, because the conclusion of CALLA is that the PFS was mainly in favor of distant metastasis. So really, it's difficult for me to understand how distant metastasis may be evaluated with the vagina visit. So really, it's very difficult to compare the two trials, but I have some concerns. And also because of toxicity in the study, unfortunately 30% of patients did not complete concurrent chemoradiation because of residual toxicity due to induction chemotherapy. So I wanted to be sure in the context of modern radiotherapy, if really induction chemo adds something to modern radiotherapy. Dr. Linda Duska: Well, I have two more questions for you. As we move immunotherapy into the front line, at least for these high risk locally advanced cervical cancer patients that were eligible for A18, what does that mean then for hopefully those few that develop recurrence in terms of second line therapy? Dr. Domenica Lorusso: Well, Linda, this is a very important question. We do not have data about immuno after immuno, but I would not completely exclude this hypothesis because in KEYNOTE-A18, the patient received treatment for a well-defined time period. And for those patients not progressing during immunotherapy, I really guess if there is a space for the reintroduction of immunotherapy at the time of recurrence. In this moment we have 30% of patients in KEYNOTE-A18 in the control arm that receive immunotherapy after progression, but still we have 11% of patients that receive immunotherapy in combination with concurrent chemoradiation and then receive, again, immunotherapy in later line of therapy. I think we need to collect these data to capture some signals and for sure we have the new drug. We have antibody drug conjugate. The trials are ongoing exploring the role of antibody drug conjugate, particularly in immune pretreated patients. So I think this is a very interesting strategy. Dr. Linda Duska: I was going to ask you, “What are the next steps,” but I think you already answered that question. You talked about the second line. If you were going to redesign a study in the frontline, what would it look like? Dr. Domenica Lorusso: Probably one question that I would like to answer – there are two questions in my opinion in KEYNOTE-A18 – one is induction immunotherapy. Linda, correct me if I'm wrong, you reported very interesting data about the immune landscape change when you use induction immunotherapy. And I think this is something that we need to explore in the future. And the second question is the duration of maintenance. Because, again, we decided for two years based only on the epidemiology of recurrence, but I guess if one year may be enough. Dr. Linda Duska: I think this sequencing question is really important, that the induction immunotherapy was actually GY017. I can't take credit for that, but I think you're right. I think the sequencing question is really important. Whether you need the concurrent IO or not is an important question. And then to your point about the 2 years, the length of the need for maintenance therapy is a question that we don't know the answer to. So there are lots of really important questions we can continue to ask. I want to thank you so much for sharing your valuable insights with us on the podcast today. You're always so thoughtful about this particular study and cervix cancer in general and also for your great work to advance the care for patients with GYN cancers. Dr. Domenica Lorusso: Thank you, Linda. It's our work - we progress together. Dr. Linda Duska: Yes. And we thank the patients as well. The over 1,000 patients that went on this trial during a pandemic. Right? Dr. Domenica Lorusso: Absolutely. Without their generosity and their trust, we would not be able to do this trial. Dr. Linda Duska: So we're very grateful to them and we thank our listeners for your time today. If you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Thank you all.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.   Follow today's speakers:  Dr. Linda Duska @Lduska Dr. Domenica Lorusso   Follow ASCO on social media:   @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn     Disclosures:   Dr. Linda Duska: Consulting or Advisory Role: Regeneron, Inovio Pharmaceuticals, Merck, Ellipses Pharma Research Funding (Inst.): GlaxoSmithKline, Millenium, Bristol-Myers Squibb, Aeterna Zentaris, Novartis, Abbvie, Tesaro, Cerulean Pharma, Aduro Biotech, Advaxis, Ludwig Institute for Cancer Research, Leap Therapeutics Patents, Royalties, Other Intellectual Property: UptToDate, Editor, British Journal of Ob/Gyn Dr. Domenica Lorusso: Consulting or Advisory Role: PharmaMar, AstraZeneca, Clovis Oncology, GSK, MSD, Genmab, Seagen, Immunogen, Oncoinvest, Corcept, Sutro Biopharma, Novartis, Novocure, Daiichi Sankyo/Lilly Speakers' Bureau: AstraZeneca, Clovis, GSK, MSD, ImmunoGen, Seagen Research Funding (Inst.): PharmMar, Clovis, GSK, MSD, AstraZeneca, Clovis Oncology, Genmab, Seagen, Immunogen, Incyte, Roche, Pharma&, Corcept Therapeutics, Alkermes Travel, Accommodations, Expenses: AstraZeneca, Clovis, GSK, Menarini  

In Part II of this series on the standard of care, Dan continues his discussion with Colleen Palmer and Lou Gale by reviewing specific examples of where contract language can elevate the standard of care – and advice on how to negotiate this language out of a design professional's agreement to ensure a balanced – and insurable agreement.  We also discuss how the standard of care is evolving and what design firms should be prepared for to mitigate their risk.  

About Michael J. Lipson OD FAAO FSLSDr. Michael Lipson is recently retired from his position as an optometrist/associateprofessor at University of Michigan. His clinical practice involves specialty contact lenses:OrthoK, keratoconus, post-corneal transplant, post-refractive surgery and severe dry eye patients. He has published peer-reviewed clinical research studies on OrthoK, vision-related quality of life, myopia management and new lens designs. He lectures nationally and internationally at live and online venues on those same topics. Dr. Lipson developed a validated questionnaire to assess vision-related quality of life for all types of vision correction, including OrthoK. He has authored chapters in textbooks on OrthoK, scleral lenses and general contact lens topics. Dr. Lipson is the author of the book “Contemporary OrthoKeratology”. He is an independent consultant to the specialtycontact lens industry relative to OrthoK education and myopia management. He is on the GPLI Advisory Board, served as Vice-President of the Scleral Lens Education Society and served on the Scleral Lens Education Society Board for many years.https://journals.lww.com/optvissci/citation/2024/07000/letter_to_the_editor__myopia_management_is_now.2.aspxhttps://pubmed.ncbi.nlm.nih.gov/38546754/

In this episode, Dr. Valentin Fuster highlights the Forest HCM study, which focuses on the withdrawal of standard care medications in patients with obstructive hypertrophic cardiomyopathy receiving afficantin. The study shows promising results: nearly half of the patients who attempted to reduce or stop their medications did so successfully, with significant improvements in functional class and symptoms. While the findings suggest that afficantin may allow for the reduction of traditional therapies, caution is advised, as not all patients may benefit equally.

The WHO recently stated that fluoride is, in fact, unsafe. After 60 years of being labeled a conspiracy theory, with experts reassuring the public about its safety, people should be concerned about taking the “experts” for their word. We should be doing our own research.   Pfizer's admission that they did not test certain aspects of their COVID-19 vaccine before marketing it as "safe" and "effective" raises serious questions. Can we keep on blindly trusting "expert" advice? In this episode, Brian Moody and Hans Toohey discuss why you need to become your own expert. They delve into what you must look out for before making decisions that greatly impact your or your family's lives. Tune in to learn about what Brian and Hans do to make more informed choices about their health and lives. Be Skeptical of What the “Experts” Say: Question everything. Just because an “expert” says something, doesn't mean it's infallible. If it concerns your body or impacts your life, take the initiative to do your own research instead of blindly trusting someone simply because they hold a PhD. Throughout history, there has been "common knowledge" that experts endorsed which later proved to be incorrect. Historical Narratives Should Be Re-examined: Don't hesitate to research and consider alternative viewpoints that challenge commonly accepted historical knowledge. Understanding that history is often presented with biases, and exploring different perspectives can give you a more comprehensive and accurate understanding of past events. Corporations Don't Want You To Get Better: Pharmaceutical companies prioritize profits over the well-being of individuals. Their decisions on product development, marketing, and distribution are driven more by financial gain than by public health benefits. Critically assess medical products and treatments, weighing their pros and cons before proceeding. Trust Yourself, Not Just Experts: Take personal responsibility and trust your own judgment. Whether it's about family health, financial decisions, or general well-being, strive to become the expert in your own life. Gather information, question the norms, and make informed decisions for the benefit of your family. Got Questions? Reach out to us at info@remnantfinance.com ⁠Visit https://remnantfinance.com for more information FOLLOW REMNANT FINANCE Youtube: @RemnantFinance (https://www.youtube.com/@RemnantFinance) Facebook: @remnantfinance (https://www.facebook.com/profile?id=61560694316588) Twitter: @remnantfinance (https://x.com/remnantfinance) TikTok: @RemnantFinance Don't forget to hit LIKE and SUBSCRIBE 

I'm sharing my latest medical adventure where the standard of care medical system tried to steer me into a hysterectomy. Why? Because a biopsy indicated complex atypical hyperplasia, and despite a CT scan showing no cancer, the recommendation was a full hysterectomy. But let me tell you, I wasn't about to jump into a life-altering surgery without peeling back every layer. And let me tell you, navigating this medical maze was a shocker. I dove into all the options, from hormone therapy to biopsies every three months, determined to advocate for my health. Through my story and insights from listeners who shared LIVE their own health hurdles, I unpack the importance of being informed and proactive. So, if you've ever felt lost in the medical system, this episode is your guide to standing firm and making empowered, educated decisions about your health. Trust me, you don't want to miss this! Shop ALL of Dr. Amie's Fixxr® Supplements: betterlifedoctor.com LET'S GET YOUR LIFE BACK...Connect with Dr. Amie Hornaman Book a free application call: https://dramiehornaman.com/pages/book-a-call FREE DOWNLOADS… What Are the Optimal Lab Ranges? What Steps Can I Take? Don't know where to start...don't know which labs are useful? And what to do when you get your results? “How To” Guide For Supplements Here's your Fixxr® supplement timeline and guide. RATE, REVIEW AND FOLLOW ON APPLE PODCASTS Show your love for Amie and The Thyroid Fixer Podcast! If you're enjoying our journey together, I'd be thrilled if you could take a moment to rate and review the show on Apple Podcasts. Your support helps me reach and help more people just like you, guiding them towards their optimal selves! Just click HERE, scroll all the way down, give us those 5 stars, and share what you enjoy about my episodes in a review. Haven't subscribed yet? Make sure to follow The Thyroid Fixer Podcast to catch all the new episodes that come out every week. Follow HERE and never miss out on a moment of the journey! CONNECT WITH ME ON SOCIAL MEDIA: Join my exclusive Facebook Group, Dr. Amie…The Thyroid Fixer®...Love Your Mirror, for a Community of HOPE and Support in your thyroid journey. https://www.facebook.com/groups/dramie/ Like me on Facebook: Amie Hornaman Nutrition and Functional Medicine Subscribe on Youtube: Dr. Amie Hornaman Follow me on Instagram: @dramiehornaman

This episode is sponsored by CurvaFix®, Inc, the makers of the CurvaFix® IM Implant – Delivering strong, minimally invasive fixation for curved anatomy and poor bone. In this podcast, Brett Crist, MD moderates a conversation about the treatment of elderly patients' who sustain immobility injuries of the pelvis and acetabulum with Julie Switzer, MD and Robert Wetzel, MD. During their conversation they dive into the clinical and economic impact of the current standard of care, how their patient care has evolved over time, patient outcomes, and more! To learn more about the CurvaFix system, please visit our website: CurvaFix

In Episode 36 of "Talk to Me About A&E," Dan is joined by Colleen Palmer, Risk Manager for Beazley, and Lou Gale, GC for the architectural firm SCB, on the Standard of Care.  In Part I of this two-part series we begin the first question asked when a design professional is accused of negligence: What was the applicable standard of care - and was it met?   This discussion will include an overview of what every design professional should know when it comes to the standard of care, as well as how best to educate their clients and manage expectations through effective communication and documentation practices.  

The documentary I want to share with you today is called "A New Standard of Care" by Megan Smith, and it's talking about holistic approaches to healing the body from cancer.About the Host:Melissa is an Integrative Health Practitioner and Master Practitioner in NLP and Timeline Therapy and a Board Designated Hypnotherapy Teacher Trainer, helping people get to the root cause of their health issues and then get lasting results. Melissa neither diagnoses nor cures but helps bring your body back into balance by helping discover your “toxic load” and then removing the toxins. Melissa offers functional medicine lab testing that helps you “see inside” to know exactly what is going on, and then provides a personalized wellness protocol using natural herbs and supplements. Melissa's business is 100% virtual – the lab tests are mailed directly to your home and she specializes in holding your hand and guiding the way to healing so that you don't have to figure it all out on your own.Melissa is the winner of the 2021 & 2022 Quality Care Award by Business From The Heart and is also the recipient of the Alignable “Local Business Person of the Year “Award 2022 for Whistler.Melissa has been featured at a number of Health & Wellness Summits, such as the Health, Wealth & Wisdom Summit, The Power To Profit Summit, The Feel Fan-freaking-tas-tic Summit, the Aim Higher Summit and many more! She has also guested on over 60 different podcasts teaching people about the importance of prioritizing our health and how to get started. Linktree: https://linktr.ee/yourguidedhealthjourney Thanks for listening!If you know somebody who would benefit from this message, or would be an awesome addition to our community, please share it using the social media buttons on this page.Do you have some feedback or questions about this episode? Leave a note in the comment section below! Subscribe to the podcast!If you would like to get automatic updates of new podcast episodes, you can subscribe on the podcast app on your mobile device.

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are one of the established treatments used to slow the progression of CKD and improve outcomes.  Could perhaps the glucagon-like peptide 1 (GLP-1) receptor agonists provide similar, additive, or different benefits in patients with CKD?  Guest Author: John Swegle, PharmD, BCPS, BCACP  Music by Good Talk

In this episode of The Standard of Care Podcast, Samantha Johnson and Nick Adams recount their journey from attending conferences to becoming conference speakers on critical medical-legal topics in EMS. They reflect on how these pivotal experiences shaped their current work. The episode dives into highlights from recent EMS conferences, such as South Carolina EMS, Metro Atlanta EMS, and FAST24, where they engaged with street-level medics and addressed critical topics in the ever-evolving landscape of EMS law. Whether you're a seasoned provider or just starting, this episode offers valuable takeaways on the value of EMS conferences, the evolution of the Standard of Care Podcast, and the importance of staying informed and involved in industry developments. Links:National Association of EMS Physicianshttps://naemsp.org/2025 Annual MeetingJanuary 6-11, 2025https://naemsp.org/annual-meeting/ South Carolina EMS Associationhttps://scemsa.org/2025 SCEMSA SymposiumMarch 5-7, 2025https://scemsa.org/ems-symposium Metro Atlanta EMS Conference2025 Metro Atlanta EMS Conference January 30-31, 2025https://www.maemsc.org/ Prisma Health Swamp Rabbit Prehospital Medicine Conference2025 Swamp Rabbit Conference June 17-19, 2025https://www.facebook.com/ghsemsconference/ FAST25(FlightBridgeED Air and Surface Transport Symposium 2025)Lexington, KY | May 19-21, 2025https://fbefast.com FTFC/Gathering of Eagles2025 FTFC/Gathering of Eagles June 9-13, 2025https://firsttherefirstcare.com/ 

Today we are joined by Dr. MedLaw. She discusses the complexities of the "standard of care" in medical malpractice cases. Dr. MedLaw explains that while the standard is meant to reflect what is recognized as acceptable and appropriate medical practice, it must also consider the specific circumstances, location, and the evolving nature of medical knowledge, allowing for some flexibility and acknowledging the role of medical judgment. Let us know what you thought of this week's episode on Twitter: @physicianswkly Want to share your medical expertise, research, or unique experience in medicine on the PW podcast? Email us at editorial@physweekly.com! Thanks for listening!

Pink Sheet reporter and editors discuss former Surgeon General Jerome Adams' views on how the FDA can better ensure clinical trial diversity (:27), questions about approving a new drug that would be used with a standard of care regimen that is off-label (15:00), and the agency beginning to schedule fully in-person advisory committee meetings (24:03). More On These Topics From The Pink Sheet ‘You Shall Not Pass:' Former Surgeon General On Why US Government Should Push Trial Diversity: https://pink.citeline.com/PS155063/You-Shall-Not-Pass-Former-Surgeon-General-On-Why-US-Government-Should-Push-Trial-Diversity Gaps Found In Most Pharma Trial Diversity Policies: https://pink.citeline.com/PS155086/Gaps-Found-In-Most-Pharma-Trial-Diversity-Policies Zevra's Arimoclomol Use With Standard Of Care Complicates US FDA Adcomm Efficacy Assessment: https://pink.citeline.com/PS155091/Zevras-Arimoclomol-Use-With-Standard-Of-Care-Complicates-US-FDA-Adcomm-Efficacy-Assessment Back To White Oak: US FDA Adcomms Go Fully In-Person, Starting With Antimicrobials Panel: https://pink.citeline.com/PS155100/Back-To-White-Oak-US-FDA-Adcomms-Go-Fully-InPerson-Starting-With-Antimicrobials-Panel

Returning guest, Grace's dad Scott Schara chats with Crash Connell. Grace's dad walks through how Standards of Care were designed to kill us and the only solution. He also gives us an update on the lawsuit surrounding Grace's wrongful death. Links: https://ouramazinggrace.net https://rumble.com/c/c-2054162   Stand Up For The Truth's Rumble Page: https://rumble.com/user/CTRNOnline Donate to our Truth mission: https://www.standupforthetruth.com/donate/

Coro Health's innovative therapeutic music services are revolutionizing care for individuals with dementia, Alzheimer's, and other conditions. David Schofman, Co-Founder and CEO of Coro Health, describes their groundbreaking Music Prescription Builder and compelling evidence from clinical trials showing significant reductions in agitation, depression, medication, and caregiver burden. Learn how digital therapeutics backed by research and world-class neuroscience can elevate the standard of care and improve health outcomes across the continuum of care. Links and notes related to this episode can be found at https://mpetersonmusic.com/podcast/episode187 Connect with us: Newsletter: https://mpetersonmusic.com/subscribe Facebook: https://www.facebook.com/EnhanceLifeMusic/ Instagram: https://www.instagram.com/enhancelifemusic/ LinkedIn: https://www.linkedin.com/in/mpetersonpiano/ Twitter: https://twitter.com/musicenhances Sponsorship information: https://mpetersonmusic.com/podcast/sponsor Leave us a review on Podchaser.com! https://www.podchaser.com/podcasts/enhance-life-with-music-909096 In-episode promo:  Sheet Music Direct https://www.sheetmusicdirect.com The Business Side of Music podcast https://www.businesssideofmusic.com   

Join us as Kate Gainer, Executive Vice President and CEO of the Iowa Pharmacy Association, discusses the transformative shifts in pharmacy practice. Learn about statewide adoption of the new pharmacy standard of care, legislative advocacy, and the future of pharmacy. Don't miss this insightful conversation! https://www.iarx.org/ https://www.bizofpharmpod.com/

Xenofon Baraliakos, MD, PhD / Philip Helliwell, MD, PhD - Can the Standard of Care Be Elevated in Spondyloarthropathies? Key Learnings From Rheumacensus Initiatives in PsA and axSpA

On April 23rd, the US Department of Labor released its final version of the “Retirement Security Rule” which outlines a higher standard of care for retirement plans. What does this mean for your retirement plan?

In this episode of Industry Matters, Respiratory Edition, Boone Lockard, VP of Clinical Services, discusses humidified high flow and how it can positively impact COPD patients. Zach Haynes, Market Development Manager - Airvo from Fisher & Paykel discusses some challenges that homecare and long-term care clinicians face and how humidified high flow therapy has helped alleviate some of these issues. 

A group of doctors has declared that it's time to protect children. Janet Parshall tells you more in her commentary for this week.See omnystudio.com/listener for privacy information.

This episode is brought to you by Cozy Earth, Maui Nui, and Lumebox. We've heard about Dr. Thomas Seyfried's groundbreaking research and approach to cancer as a disease of metabolic dysfunction. Today's guest was inspired by Dr. Seyfried's metabolic approach and conducted his own research on brain cancer cells using ketone-based metabolic therapy and hyperbaric oxygen. His findings were mind-blowing! Today on The Dhru Purohit Podcast, Dhru sits down with Dr. Dominic D'Agostino to discuss his extensive research on brain cancer cells placed in ketosis and under the pressure of hyperbaric oxygen. Dr. D'Agostino shares why his findings provide further insight into the idea that cancer cell growth can be metabolically managed. He also discusses how exercise and a low-carbohydrate diet can be used as metabolic therapies to reduce cancer risk. Dr. D'Agostino shares the critical tests we should focus on to assess our metabolic health and the essential supplements that can support ketosis.  Dr. Dominic D'Agostino is an Assistant Professor at the University of South Florida College Of Medicine, Molecular Pharmacology & Physiology, where he develops and tests metabolic therapies, including alternative energy substrates and ketogenic agents for neurological disorders, cancer, and wound healing. While studying the effects of gasses on the brains of Navy Seal divers, he developed an approach for metabolically starving cancer cells through diet and compressed oxygen, replacing chemotherapy, surgery, or radiation.   In this episode, Dhru and Dr. D'Agostino dive into (audio version / Apple Subscriber version): The most innovative approaches to cancer (00:00:11 / 00:00:11)  The metabolic approach to cancer (1:30/1:30) Using the hyperbaric approach in cancer patients (13:00/ 9:03) The results of Dr. A'gostino's studies on mice (17:00 / 13:50) How this research translates to patients (22:00 / 18:05) Why a ketogenic diet can be therapeutic (37:00 / 32:04) The role of exercise in cancer prevention (53:00 / 46:35) What lifestyle factors should we be doubling down on for prevention (55:00 / 50:14) Dr. D'Agostino's thoughts on a low carbohydrate diet (1:01:00 / 56:30) The therapeutic benefits of ketosis (1:11:00 / 1:06:40) Supplements that can support ketosis (1:19:00 / 1:12:43) How to measure for ketosis (1:24:00 / 1:18:30) Checking the status of your metabolic health (1:26:00 / 1:21:30) Where to find community (1:34:00 / 1:28:16) Also mentioned in this episode: Keto Start Donate to the University of Florida (Metabolic Therapy and Cancer Research #250244) Levels  To learn more about Dr. D'Agostino, follow him on Instagram, Twitter, or his website.  Right now, get 40% off your Cozy Earth sheets. Just head over to cozyearth.com and use code DHRUP. Right now, Maui Nui Venison is offering my community 20% off your first purchase. Just go to mauinuivenison.com/DHRU or enter the code D-H-R-U at check out to get 20% off and up your high-quality protein today. Lumebox is offering my community $260 off their FDA-approved portable Red Light device! That's over 40% off! Go to thelumebox.com/dhru and get your Red Light device. 

Filmmaker journalist Megan Smith lost her husband to cancer and then began traveling to alternative-health clinics around the world, to learn about other options. We discuss her new film and...

Megan S. Smith, M.S. Megan Smith and guest host Scott Schara drill down the propaganda surrounding cancer, cures, and the lies that are behind the agenda to hasten our death. This is a must listen to podcast for anyone who is not awake to the cancer narrative. Please watch Megan's documentary, A New Standard of Care https://anewstandardofcare.com/       Shameless plug for swag for our listeners/donors! https://www.redpillprints.com/stand-up-for-the-truth - Thanks for YOUR Support!    

The McCullough Report with Dr. Peter McCullough – Syndromes and diseases occurring as post-acute sequelae are caused by the Spike Protein and the inflammation and damage it inflicts on the body. While various supplements and medications can manage symptoms, McCullough Protocol Base Spike Protein Detoxification is the only published method offering...